VIP: Vasoactive Intestinal Peptide for CIRS

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/vip-cirs-protocol

Educational content only. Not medical advice. VIP for CIRS requires a CIRS-experienced practitioner and proper diagnostic workup; this article does not constitute a treatment protocol.

Overview

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide originally isolated from porcine intestine in the 1970s and now recognized as a wide-spectrum signaling molecule. It acts across the nervous, immune, pulmonary, cardiovascular, and gastrointestinal systems — modulating cytokine release, supporting vasodilation, and influencing T-regulatory cell behavior. In clinical peptide medicine, intranasal VIP is best known as the final step of the Shoemaker Protocol for Chronic Inflammatory Response Syndrome (CIRS), where it is used to help re-regulate a chronically dysregulated innate immune response after upstream contributors have been addressed.

VIP is not a general performance or longevity peptide. Its clinical role in CIRS is highly specific, requires precise sequencing, and depends entirely on the patient being in a remediated environment with prior protocol steps completed.

Key Properties

• 28-amino-acid neuropeptide of the secretin/glucagon superfamily
• Signals primarily through VPAC1 and VPAC2 G-protein-coupled receptors
• Anti-inflammatory effects on macrophages, dendritic cells, and T-regulatory cells
• Pulmonary and systemic vasodilator
• Modulates TGF-β1, MMP-9, C4a, and MSH in CIRS patients
• Administered intranasally in the Shoemaker Protocol; very short plasma half-life when given systemically

What CIRS Is

Chronic Inflammatory Response Syndrome was described by Ritchie Shoemaker, MD, beginning in the late 1990s. It is conceptualized as a biotoxin-driven, multi-system, multi-symptom illness occurring in genetically susceptible individuals who cannot efficiently clear certain biotoxins.

Common triggers include:

• Exposure to water-damaged buildings (mold, mycotoxins, actinomycetes, endotoxins)
• Tick-borne co-infections (Borrelia, Babesia)
• Ciguatera fish poisoning
• Cyanobacteria (Pfiesteria, blue-green algae)

Susceptibility is strongly linked to specific HLA-DR/DQ haplotypes, which impair antigen presentation and biotoxin clearance. Symptoms typically span multiple systems:

• Cognitive: brain fog, word-finding issues, executive dysfunction
• Fatigue: post-exertional malaise, unrefreshing sleep
• Respiratory: shortness of breath, exercise intolerance, chronic sinus issues
• GI: abdominal pain, altered motility
• Other: static shocks, ice-pick pains, vertigo, polyuria/polydipsia, temperature dysregulation

Diagnosis is built from exposure history, Visual Contrast Sensitivity (VCS) testing, HLA typing, and a defined panel of inflammatory and hormonal labs.

Why VIP in CIRS

CIRS is characterized by a measurable pattern of innate immune dysregulation. Among the consistently observed abnormalities:

• Elevated TGF-β1 — drives tissue remodeling and pulmonary hypertension
• Elevated MMP-9 — increases blood-tissue barrier permeability
• Elevated C4a — innate complement activation
• Low MSH — pituitary dysfunction with downstream hormonal effects
• Elevated VEGF early, low VEGF later — capillary hypoperfusion
• Dysregulated NLRP3 inflammasome activity

VIP, signaling primarily through VPAC1 and VPAC2 receptors, has been shown in research and clinical settings to down-regulate TGF-β1, normalize MMP-9, support pulmonary artery pressures, restore MSH, and improve cellular energy patterns on metabolic testing. In the Shoemaker model, this is why VIP is reserved for the final repair phase: once biotoxin input and infectious drivers are removed, VIP helps the regulatory system return to baseline.

The Shoemaker Protocol — VIP's Position

The Shoemaker Protocol is a sequenced, 13-step treatment framework. VIP sits at Step 12 — late, deliberate, and conditional. The earlier steps include exposure removal, binders (cholestyramine or welchol), MARCoNS eradication, gluten/amylose adjustments, androgen and antidiuretic hormone correction, MMP-9 management, VEGF correction, C3a/C4a management, and TGF-β1 management.

Key principle: VIP is not first-line. It is not used as a stand-alone "anti-inflammatory peptide," it is not indicated for non-CIRS conditions, and Shoemaker-trained clinicians do not introduce it until the prior steps are documented as complete on repeat labs.

The simplified order of operations:

1. Remove from exposure (the single most important step)
2. Initiate binders (cholestyramine or welchol) to clear biotoxins
3. Eliminate MARCoNS (multiply antibiotic-resistant coagulase-negative staph)
4. Correct gluten/amylose sensitivities
5. Correct androgens
6. Correct ADH and osmolality
7. Correct MMP-9
8. Correct VEGF
9. Correct C3a
10. Correct C4a
11. Reduce TGF-β1
12. VIP — restore regulatory function
13. Re-test and confirm sustained remission

Required Prerequisites Before VIP

Starting VIP out of sequence is the most common reason patients fail to respond — or worsen. The following must be in place:

Dosing Protocols (Shoemaker)

VIP is delivered intranasally via a compounded nasal spray, typically formulated at 50 mcg per spray.

Some practitioners begin with once- or twice-daily dosing and titrate up over the first week. Total daily dose at full maintenance is generally 200 mcg/day intranasally. Courses commonly extend many months; some patients remain on a reduced maintenance schedule long-term under supervision.

Monitoring

Response is tracked objectively, not just symptomatically. The Shoemaker labs panel is repeated at defined intervals.

If lipase rises above 90 U/L during therapy, VIP is typically paused.

Expected Outcomes

VIP is a gradual repair therapy, not an acute fix. Reported and clinically observed patterns:

• Weeks 2-4: Subtle shifts in sleep quality, reduction in static shocks and ice-pick pains, improved VCS scores
• Weeks 4-8: Cognitive clarity, reduced word-finding issues, sustained mental stamina
• Weeks 8-12: Resolution of post-exertional malaise, restored exercise tolerance, normalized resting heart rate trends
• Months 3-6: Continued improvement in inflammatory labs, stabilization of PASP, more durable symptom remission

Response is heterogeneous. Patients with longer illness duration, multiple exposures, or unresolved co-infections may respond more slowly.

Side Effects & Safety

VIP intranasally is generally well-tolerated when the protocol is followed. Reported effects include:

• Transient nasal irritation or burning
• Brief facial flushing
• Mild headache, especially in the first week
• Lightheadedness with rapid dosing increases

More serious considerations:

• Lipase elevation / pancreatitis risk — the rationale for the < 90 U/L threshold and ongoing lipase monitoring
• Paradoxical worsening — patients who start VIP while still exposed, MARCoNS-positive, or with unresolved upstream markers may worsen, sometimes significantly
• Pulmonary hypertension — VIP affects pulmonary vasculature; PASP must be characterized before therapy

Contraindications include pregnancy, breastfeeding, active malignancy, ongoing biotoxin exposure, and inability to complete the prerequisite workup.

What VIP is NOT

This is the section that prevents harm.

• Not a "feel better" peptide for otherwise healthy adults
• Not appropriate for non-CIRS chronic fatigue, generic "inflammation," or undefined post-viral syndromes outside a CIRS workup
• Not a substitute for environmental remediation — VIP cannot out-pace ongoing mold or biotoxin exposure
• Not validated as a stand-alone Long COVID therapy, despite anecdotal interest; clinical use here is investigational and should be framed as such
• Not a peptide for self-experimentation. Shoemaker explicitly specifies the clinical context; using it outside that context discards the safety scaffolding the protocol depends on

Stacking & Co-Therapy

Within the Shoemaker framework, VIP is layered on top of an already-established treatment stack rather than combined with unrelated peptides.

• Binders (cholestyramine, welchol) continued if any residual exposure history
• Hormone replacement as indicated by labs (DDAVP for ADH issues, androgens, thyroid)
• Nasal therapies post-MARCoNS clearance for biofilm prevention
• Ongoing environmental hygiene — HEPA filtration, dust control, repeat HERTSMI-2 testing

Avoid: Stacking VIP with unrelated growth-hormone secretagogues, immune-stimulating peptides (e.g., thymic peptides) outside CIRS-specific reasoning, or starting VIP without baseline Shoemaker labs. The protocol is sequenced for a reason — adding noise obscures whether VIP is helping.

Practitioner Requirement

VIP for CIRS is not a self-administered protocol. It requires a clinician trained in the Shoemaker Protocol or with documented CIRS experience.

A qualified clinician will:

• Confirm CIRS diagnosis with HLA, VCS, exposure history, and the lab panel
• Verify environmental remediation
• Sequence the prior 11 steps and document completion
• Order and interpret repeat labs including lipase and PASP
• Prescribe compounded intranasal VIP through a reputable compounding pharmacy
• Manage dose titration and recognize paradoxical responses

Self-sourcing VIP as a research chemical, dosing without baseline labs, or skipping prerequisite steps is strongly discouraged — it represents the highest-risk way to use this peptide.

Frequently Asked Questions

Q: Can I try VIP without a formal CIRS diagnosis? A: This is not recommended. The protocol's safety profile depends on the prerequisites being met and tracked. Without a workup, you cannot tell whether you are responding or being harmed.

Q: How do I get VIP prescribed? A: Through a CIRS-experienced clinician who writes a prescription to a compounding pharmacy. VIP is not a stocked retail medication; it is compounded as an intranasal spray.

Q: Is VIP useful for Long COVID? A: Some clinicians explore VIP for post-COVID inflammatory patterns that resemble CIRS, but the evidence base is preliminary. If pursued, it should be inside a CIRS-style workup with the same prerequisites and monitoring.

Q: Can I stack VIP with a mold detox protocol? A: VIP comes after binder phases in the Shoemaker sequence. Ongoing low-dose binders are common; aggressive new detox starts during VIP are generally avoided so that any worsening can be attributed correctly.

Q: After several years on VIP, do I need time off? A: Many patients taper to lower-frequency dosing once labs normalize and remain stable. Some discontinue entirely after sustained remission. Decisions are made on repeat labs and clinical status, not the calendar.

Q: Compounded VIP vs research-chemical VIP — what's the difference? A: Compounded VIP from a licensed pharmacy is prescribed, identity- and potency-tested, and formulated for intranasal use. Research-chemical VIP is not intended for human use, has variable purity, and lacks the formulation control required for nasal dosing. The Shoemaker Protocol assumes pharmacy-grade material.

Q: What if my lipase rises during therapy? A: Standard practice is to pause VIP, re-check lipase, investigate other causes (alcohol, medications, gallbladder), and resume only when lipase is < 90 U/L and the clinician agrees.

Q: Will VIP work if I'm still living in a water-damaged building? A: No — and it may make things worse. Environmental remediation or relocation is non-negotiable before VIP.

Related Content

• Compounding Pharmacy Guide
• Bloodwork Checklist
• Doctor Conversation Script
• Cerebrolysin Protocol
• COA Reading Guide

Disclaimer: This content is for educational purposes only and is not medical advice. VIP for CIRS is a specialized therapy that requires a Shoemaker-certified or CIRS-experienced practitioner, baseline diagnostic workup, environmental remediation, and ongoing laboratory monitoring. Consult a qualified healthcare provider before considering any peptide protocol. References to Shoemaker and Ryan research are made generically for educational context.

Source: https://peptides.nyc/learn/vip-cirs-protocol